Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 6/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377050 | 1.00 | CTSS (0.53) | CTSSCTSKCNR2ITGB3ITGA2B | |
| SCHEMBL3376664 | 0.89 | CTSS (0.48) | CTSSCTSKITGB3ITGA2BMEN1 | |
| SCHEMBL3376667 | 0.89 | CTSS (0.48) | CTSSCTSKITGB3ITGA2BMEN1 | |
| SCHEMBL1349362 | 0.87 | CTSS (0.51) | CTSSCTSKITGB3ITGA2BGAA | |
| SCHEMBL20592740 | 0.87 | CTSK (0.51) | CTSSCTSKITGB3ITGA2BMEN1 | |
| SCHEMBL1349363 | 0.87 | CTSS (0.51) | CTSSCTSKITGB3ITGA2BGAA | |
| SCHEMBL11595296 | 0.87 | CTSS (0.51) | CTSSCTSKITGB3ITGA2BKMT2A | |
| SCHEMBL20592743 | 0.87 | CTSK (0.51) | CTSSCTSKITGB3ITGA2BMEN1 | |
| SCHEMBL7271316 | 0.86 | POLB (0.53) | CTSSCTSKITGB3ITGA2BGPR88 | |
| SCHEMBL1554765 | 0.86 | GPR88 (0.54) | CTSSCTSKGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | CTSS 1187/4885CTSK 1484/4885CNR2 386/4885 |
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885CNR2 173/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885CNR2 173/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | CTSS 1869/4885CTSK 1094/4885CNR2 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.